By Kevin E. Noonan — There are some cases where the Federal Circuit makes its decision based on the eternal verities of patent law (insofar as there are any eternal verities in patent law). One such decision arose earlier this month when the Federal Circuit affirmed a determination of non-obviousness by the Patent Trial and Appeal Board in an inter partes review proceeding, that opinion captioned Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. The case arose incident to ANDA litigation between the parties involving Corcept’s Korlym product comprising the active pharmaceutical ingredient mifepristone for treating Cushing’s Syndrome. The drug…
